Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice

Cancer Immunology, Immunotherapy

Volumn 64, Issue 4, 2015, Pages 429-436

  Ito, Hiroyasu ^a   Ando, Tatsuya ^a   Ogiso, Hideyuki ^a   Arioka, Yuko ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Induced nitric oxide synthase; Th1; Toll like receptor agonists

Indexed keywords

IMIQUIMOD; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12P40; INTERLEUKIN 2; N(G) NITROARGININE METHYL ESTER; TOLL LIKE RECEPTOR 7; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; MEMBRANE PROTEIN; MESSENGER RNA; NOS2 PROTEIN, MOUSE; TLR7 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME INHIBITION; LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TH1 CELL; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE SYNTHASE TYPE II; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7; TUMOR CELLS, CULTURED;

EID: 84925461090     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1644-6     Document Type: Article

References (26)

1. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384
2. Conroy H, Marshall NA, Mills KH (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27:168–180
3. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320
4. Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F (2001) Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 67:709–713
5. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41–44
6. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13:721s–726s
7. Ito H, Koide N, Morikawa A, Hassan F, Islam S, Tumurkhuu G et al (2005) Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells. J Endotoxin Res 11:213–219
8. Karlsson A, Jagervall K, Utkovic H, Karlsson L, Rehnstrom E, Fredin MF et al (2008) Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. Biochem Biophys Res Commun 367:242–248
9. Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M et al (2009) Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes. Biochem Biophys Res Commun 378:579–583
10. Shirota H, Klinman DM (2011) CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother 60:659–669
11. Ito H, Ando T, Ando K, Ishikawa T, Saito K, Moriwaki H et al (2014) Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2,3-dioxygenase activity. Immunology 142:614–623
12. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I et al (2006) Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest 86:254–261
13. Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M et al (2009) Role of TNF-alpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model. J Immunol 182:391–397
14. Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32:305–315
15. Connolly DJ, O’Neill LA (2012) New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 12:510–518
16. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C (2012) Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 7:29–54
17. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
18. Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, Newberry RD et al (2010) Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 184:3907–3916
19. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W (2003) The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149(Suppl 66):53–56
20. Weber G, Caruana I, Rouce RH, Barrett AJ, Gerdemann U, Leen AM et al (2013) Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia—implications for immunotherapy. Clin Cancer Res 19:5079–5091
21. Mortenson ED, Park S, Jiang Z, Wang S, Fu YX (2013) Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 19:1476–1486
22. Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S et al (2013) Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother 62:1053–1060
23. Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K et al (2008) Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol 20:869–879
24. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol 41:1002–1007
25. Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM et al (2010) Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 184:5360–5367
26. Blesson S, Thiery J, Gaudin C, Stancou R, Kolb JP, Moreau JL et al (2002) Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 14:1169–1178